Drug Profile
NI 2201
Alternative Names: Anti-CD19 ADC; IKS 03; LCB 73; NI-2201Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator LegoChem Biosciences; NovImmune SA
- Developer Iksuda Therapeutics; LegoChem Biosciences; Light Chain Bioscience
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I B-cell lymphoma
- Preclinical Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical study in B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 05 Sep 2023 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater, Late-stage disease) in Canada, Australia (IV) (NCT05365659)
- 05 Sep 2023 Phase-I clinical trials in B-cell lymphoma (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT05365659)